| The therapeutic field | Project name | Dosage form/specification | Category | Indications | Remark |
|---|---|---|---|---|---|
| Anti-tumor drugs | Entritinib | Capsule/100mg, 200mg | Category 4 chemical drugs |
Solid tumor; Non-small cell lung cancer (NSCLC) |
Pilot study |
| Carfilzomib | Injection (lyophilized)/10 mg, 30 mg, 60 mg | Category 4 chemical drugs |
Combination therapy with dexamethasone is indicated for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least 2 prior therapies, including proteasome inhibitors and immunomodulators |
Pilot study |
|
| Rucotinib phosphate | Tablets/5mg, 15mg, 20mg Cream/1.5% |
Category 3 chemical drugs |
Chronic idiopathic myelofibrosis (PMF), myelofibrosis secondary to polycythemia vera (PPV-MF), or myelofibrosis secondary to essential thrombocythemia (PET-MF) |
Pilot study |
|
| Irinotecan liposome injection | Injection | Category 4 chemical drugs |
In combination with 5-fluorouracil (5-FU) and folinic acid (LV) in patients with metastatic pancreatic cancer who have progressed after gemcitabine therapy. |
Technology transfer |
